UK multiple sclerosis charity raises concern over Ocrevus funding

A UK patient advocacy group has rallied patients behind a call for Ocrevus (ocrelizumab) to be funded through the country’s national healthcare provider for primary progressive multiple sclerosis (PPMS).

In June of 2018, the UK’s reimbursement agency - the National Institute for Health and Care Excellence (NICE) - backed the drug for relapsing-remitting multiple sclerosis (RRMS).

However, the agency subsequently failed to reach a deal with Swiss drugmaker Roche (ROG: SIX) on reimbursement for PPMS, the most debilitating form of the disease.